The design, synthesis, and
biological evaluation of several unsaturated acyclonucleosides related to augustmycin A are described. The (propargyloxy)methyl acyclonucleoside analogues of
6-chloropurine,
adenine,
6-methoxypurine,
hypoxanthine,
6-mercaptopurine, and
azathioprine have been prepared. The 9-[(propargyloxy)methyl]
adenine (5) and 9-[(propargyloxy)methyl]
hypoxanthine (12) analogues were converted to the corresponding 5'-tributylstannyl intermediates (9 and 13), respectively, which gave 9-[[[(Z)-5-iodo-5-propenyl]oxy]methyl]
adenine (10) and 9-[[[(Z)-5-iodo-5-propenyl]oxy]methyl]
hypoxanthine (14), respectively, after iododestannylation. The [125I]-radiolabeled congeners of 10 and 14 were prepared as potential metabolic markers. Among the unsaturated acyclonucleosides tested, 9-[(propargyloxy)methyl]-6-chloropurine (3), 9-[(propargyloxy)methyl]-
6-mercaptopurine (15), 9-[(propargyloxy)methyl]
azathioprine (17), and
angustmycin A analogue 10 showed inhibition of
cancer cell growth, but only at a minimal level, and 17 also showed 14%
cancer cell death in vitro. Compound 10 provided approximately 50% protection against HIV
at 10(-4) M concentrations. Biodistribution results of [125I]-10 in mice indicate that compound 10 is readily metabolized via deiodination in vivo, possibly by serving as a substrate for the
enzyme S-adenosyl-L-
homocysteine hydrolase.